Curapath is a European Contract Development and Manufacturing Organization (CDMO) specialized in polymer- and lipid-based non-viral drug delivery systems and their components. This includes the development and manufacturing of polymer and lipid excipients, lipid nanoparticles (LNPs), polymer nanoparticles (PNPs), and advanced drug conjugation strategies. We support regulated biotech, pharmaceutical, and medical device programs from early development through GMP and commercial manufacturing.
Curapath offers a combination of off-the-shelf R&D and GMP-grade materials, as well as custom development services, enabling our partners to progress efficiently from early feasibility to scalable and regulatory-ready manufacturing. Our solutions include PEG alternatives, active targeting strategies for lipid nanoparticles (LNPs), and tunable transfection reagents, all designed with a strong focus on manufacturability, reproducibility, and long-term regulatory compliance, supporting both clinical and commercial supply of advanced delivery technologies.
To know more about Curapathclick here
To know more about the team click here
GMP Manufacturing Services
• GMP manufacturing of polymers, lipids, bioconjugates, and drug substances
• End‑to‑end drug product manufacturing (LNP, tLNP, PNP, polymer nanoparticles, liposomes ,microparticles, Plga based nanoparticles )
• Aseptic Fill & Finish operations (liquid and lyophilized formats)
• Process development, scale‑up, tech transfer, and commercial readiness
• Analytical method development, validation, and ICH stability studies
• Full CMC and regulatory support (IND/BLA preparation)
Formulation Development Services
• Nanoparticle formulation development: LNP, tLNP, PNP, PLGA/PLA, hydrogels
• Scalable nanoparticle production (from 0.8 mL to >50 L)
• Process characterization and optimization
• In vitro and in vivo support through partner networks
• Comprehensive characterization (DLS, HPLC, UV/Vis, qPCR, etc.)
Analytical & Quality Services
• Analytical method development and validation
• Stability, compatibility, and nanoparticle characterization studies
• Release testing, sterility assurance, and quality oversight
• Non‑compendial method development for complex modalities
Custom Synthesis Services
• Off the shelf polymers and lipids: PSar, PAOx, PGA, PLL, ionizable lipids
• Polymer–drug conjugation and polymer–biologic conjugation services
• Tailor‑made excipients and specialty components
• Multi‑kg scale custom polymer production
Solutions
Transfection reagents for DNA Delivery
• STAR‑CXP polymer platform for in vivo DNA delivery
• High‑efficiency transfection reagents for DNA, mRNA, and peptides
• Nanoparticle stabilizers that improve safety and performance
PEG‑Free Shielding Lipids for LNP and PNP
• Polysarcosine (PSar) shielding lipids for PEG‑free LNPs
• PGA‑diol and PAOx shielding lipids for higher stability, performance and freeze dried LNPs
• Next‑generation excipients for RNA, protein replacement, and vaccines
Biologic Solubilization Solutions
• Oleyl‑PSar solubilizers for improved protein, peptide, and mAb stability
• Alternatives to polysorbates and poloxamers
• Polymer–biologic conjugation solutions (PSarylation)
Polymer–Drug Conjugation Solutions
• PGA, PLys, PArg, and other backbones for enhanced drug solubility and targeting
• Biodegradable and tunable architectures for oncology and immunology applications
Medical Device Polymer Coating Solutions
• Antimicrobial and non‑fouling polymer coatings
• High‑performance biocompatible coatings
• Industrial and medical‑grade multi‑kg scale options
Ready‑to‑Use Nanoparticle Solutions
• FTO ionizable lipid library for LNP formulation
• Ready‑to‑use LNP systems for mRNA and RNA therapeutics
• Enhanced in vivo expression profiles vs. benchmark lipids
Targeted Lipid Nanoparticles for extrahepatic Delivery
• Ligand‑functionalized LNPs using CliCr® chemistry
• Targeted delivery to lung, T‑cell, CNS, and bone marrow tissues
• High‑density ligand attachment with preserved nanoparticle integrity
Curapath is more than CDMO , is a true strategic partner in the development of advanced therapeutics. We work side by side with our clients across the entire journey, from early formulation and proof of concept to GMP manufacturing and beyond, providing not only high-quality materials and scalable processes, but also tailored solutions that enhance efficiency, de-risk development, and accelerate time to clinic.
For this reason, our core values are:
• We care: We develop our people, act with a strong customer focus, respect our partners, and keep patients at the center of everything we do.
• We never give up: We think outside the box, design, test, adapt, and continuously improve to overcome challenges.
• We welcome challenges: We embrace complexity as an opportunity to drive scientific innovation and operational excellence, creating real value for our partners.
Curapath partners with a diverse range of organizations across the advanced therapeutics landscape, adapting our capabilities to each stage of development and specific technological needs. Our typical customers include:
• Biotech startups and emerging companies: Supporting early-stage programs with formulation development, proof of concept, and scalable processes to accelerate their path to clinic.
• Pharmaceutical and biotech companies: Enabling the development and manufacturing of advanced drug delivery systems, from preclinical stages to GMP and commercial supply.
• Gene and cell therapy developers: Providing tailored solutions for RNA/DNA delivery, including LNPs, PNPs, and advanced targeting strategies.
• Academic institutions and research centers: Collaborating on innovative projects, feasibility studies, and technology transfer to translate research into real therapeutic applications.
• Medtech and combination product companies: Supporting the integration of advanced delivery systems into medical devices and combination therapies.
In all cases, we act not just as a supplier, but as a development partner—bringing flexibility, technical expertise, and a strong focus on long-term collaboration.
